The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. Therefore, Antibody generation and engineering is a growing area with lots of exciting developments and many clinical achievements.

At the 1st Therapeutic Antibody Workshop: along the path from Target Genes to Patients, you will attend a full day of intensive instructional presentations that will take you from the desired target identification concepts through real world applications. This workshop will be taught by scientists with long experience, who will focus on content applicable to current research goals, available antibody platform technologies, process development, GMP production, regulatory preclinical studies and clinical applications. The presentations will include real-life case studies, problems encountered and solutions applied, along with extensive coverage of theory and background. At the same time, examples of how different expertise may be combined will be provided. Each presentation will offer a mix of formal lecture and interactive discussions and activities to maximize the learning experience.

We are sure that you will enjoy very much this exciting Workshop.

• 8.30 Registration
• 9.00 Basic principles of Antibodies, Angela Santoni, Università La Sapienza, Roma
• 9.30 Learning from healthy controls and patients: the strategy of human B cell memory development, Rita Carsetti (Ospedale Pediatrico Bambin Gesù, Rome)
• 10.00 Genetic vaccines and other tricks to generate great monoclonal antibodies, Giuseppe Roscilli (Takis Biotech, Rome)
• 10.30 Phage Display Libraries, Christian Steinkühler (Exiris)

•  11.00 Coffee Break & Networking

•  11.30 Generating human antibodies in the mouse: the Trianni platform, Gloria Esposito (Austrianni)
• 12.00 Synthetically engineered DNA-encoded monoclonal antibodies ( DMAbs): a new therapeutic strategy for many diseases, Kevin Hollevoet, University of Leuven
• 12.30 Preclinical models for proof of concept studies, Emanuele Marra /TBD (Takis Biotech)

• 13.00 Lunch Break & Networking

• 14.00 Antibody Process Development, Stefano Franceschini (IBI Lorenzini)
• 14.30 GMP Production: Theoretical and practical aspects, Valentina Flacca (Menarini Biotech)
• 15.00 Strategies of preclinical safety assessment of monoclonal antibodies, Isabella Andreini (AkrosBioscience)
• 15.30 Experiences from a preclinical CRO in regulatory toxicity study with monoclonal antibodies, Laura Monetini (ERBC)
• 16.00 Clinical trials, program allocation e regulatory challenges, Elizabeth Shields (MSD Italia)
  
• 16.30 Networking in Lazio (1): Rever3mab project,  Luigi Aurisicchio (Takis Biotech)
• 17.00 Networking in Lazio (2): The MenHub experience, Leonardo Sibilio (Menarini Biotech)
• 17.30 Adjourn